Denali Therapeutics Inc
NASDAQ:DNLI

  • LAST PRICE
    29.8900
  • TODAY'S CHANGE (%)
    -1.6900 (-5.3515%)
  • Bid / Lots
    23.0000/ 1
  • Ask / Lots
    32.6900/ 1
  • Open / Previous Close
    31.0700 / 31.5800
  • Day Range
    29.5000
    31.4700
  • 52 Week Range
    14.5600
    33.3300
  • Volume
    934,439

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
DNLI
Denali Therapeutics Inc
4.5B
-10.8x
---
CRSP
CRISPR Therapeutics AG
4.7B
-18.1x
---
AXSM
Axsome Therapeutics Inc
4.4B
-15.3x
---
RARE
Ultragenyx Pharmaceutical Inc
4.7B
-7.4x
---
TGTX
TG Therapeutics Inc
4.8B
-289.7x
---
ADMA
ADMA Biologics Inc
5.3B
154.9x
---
As of 2024-11-12

Company Information

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).

Contact Information

Headquarters
161 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1910
Phone
650-866-8548
Fax
302-655-5049

Executives

Independent Chairman of the Board
Vicki Sato
President, Chief Executive Officer, Director
Ryan Watts
Chief Financial Officer, Chief Operating Officer, Company Secretary
Alexander Schuth
Chief Medical Officer
Carole Ho
Director
Steven Krognes

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$4.5B
Revenue (TTM)
$0.00
Shares Outstanding
143.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.42
EPS
$-2.76
Book Value
$7.45
P/E Ratio
-10.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.